Premium
A retinoic acid receptor agonist tamibarotene suppresses iron accumulation in the liver
Author(s) -
Yoshikawa Osamu,
Ebata Yu,
Tsuchiya Hiroyuki,
Kawahara Arisa,
Kojima Chihiro,
Ikeda Yoshito,
Hama Susumu,
Kogure Kentaro,
Shudo Koichi,
Shiota Goshi
Publication year - 2013
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.20013
Subject(s) - endocrinology , medicine , ferroportin , retinoic acid , agonist , chemistry , receptor , downregulation and upregulation , retinoic acid receptor , insulin resistance , hepcidin , insulin , biochemistry , anemia , gene
Objective: Hepatic iron overload (HIO) and iron‐induced oxidative stress have recently emerged as an important factor for the development and progression of insulin resistance. The aim of this study was to evaluate the effect of tamibarotene, a selective retinoic acid receptor α/β agonist, on hepatic iron metabolism, based on our previous findings that retinoids suppress hepatic iron accumulation by increasing hepatic iron efflux through the regulation of hemojuvelin and ferroportin expression. Design and Methods: We quantitated the non‐heme iron content and iron metabolism‐related gene expression in the liver, and serum lipid and blood glucose levels in KK‐ A y mice after dietary administration of tamibarotene. Results: It was demonstrated that tamibarotene significantly reduced blood glucose and hepatic iron, but not serum lipids, and that hemojuvelin expression significantly decreased while ferroportin increased, as observed previously. Conclusions: These results suggest that tamibarotene is a promising alternative for the treatment of insulin resistance associated with HIO.